{"pmid":32451352,"title":"SARS-CoV-2: Viral Mechanisms and Possible Therapeutic Targets - What to learn from Rheumatologists?","text":["SARS-CoV-2: Viral Mechanisms and Possible Therapeutic Targets - What to learn from Rheumatologists?","It was with great interest that we read the letter from Randy Cron and collaborators ((1)) linking the cytokine storm syndrome (CSS) seen in macrophage activation syndrome, common in the rheumatological setting, with the CSS postulated to be a background in the novel coronavirus (SARS-CoV-2) infection. Amid the high contagiousness of the virus, science was also infected by an infodemia, compelled to enter a race to find effective therapies studying mechanisms molecular aspects of SARS-CoV-2 concomitant to urgent bedside manage of patients.","J Rheumatol","Mouraa, Carlos Antonio","Cerqueira de Sant'Ana Costa, Ana Luisa","32451352"],"abstract":["It was with great interest that we read the letter from Randy Cron and collaborators ((1)) linking the cytokine storm syndrome (CSS) seen in macrophage activation syndrome, common in the rheumatological setting, with the CSS postulated to be a background in the novel coronavirus (SARS-CoV-2) infection. Amid the high contagiousness of the virus, science was also infected by an infodemia, compelled to enter a race to find effective therapies studying mechanisms molecular aspects of SARS-CoV-2 concomitant to urgent bedside manage of patients."],"journal":"J Rheumatol","authors":["Mouraa, Carlos Antonio","Cerqueira de Sant'Ana Costa, Ana Luisa"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32451352","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3899/jrheum.200657","locations":["Rheumatologists"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667881798388940800,"score":9.490897,"similar":[{"pmid":32335512,"title":"Absence of severe complications from SARS-CoV-2 infection in children with rheumatic diseases treated with biologic drugs.","text":["Absence of severe complications from SARS-CoV-2 infection in children with rheumatic diseases treated with biologic drugs.","We read with interest the Editorial by Cron and Chatam (1) suggesting a cytokine storm syndrome (CSS) occurring in response to SARS-CoV-2 infection and, consequently, a possible role for targeted approaches to blocking inflammatory cytokines.","J Rheumatol","Filocamo, Giovanni","Minoia, Francesca","Carbogno, Simone","Costi, Stefania","Romano, Micol","Cimaz, Rolando","32335512"],"abstract":["We read with interest the Editorial by Cron and Chatam (1) suggesting a cytokine storm syndrome (CSS) occurring in response to SARS-CoV-2 infection and, consequently, a possible role for targeted approaches to blocking inflammatory cytokines."],"journal":"J Rheumatol","authors":["Filocamo, Giovanni","Minoia, Francesca","Carbogno, Simone","Costi, Stefania","Romano, Micol","Cimaz, Rolando"],"date":"2020-04-27T11:00:00Z","year":2020,"_id":"32335512","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.3899/jrheum.200483","topics":["Treatment"],"weight":1,"_version_":1666138494123114496,"score":219.9043},{"pmid":32425294,"pmcid":"PMC7227559","title":"Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes.","text":["Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes.","A subset of patients with severe COVID-19 develop profound inflammation and multi-organ dysfunction consistent with a \"Cytokine Storm Syndrome\" (CSS). In this review we compare the clinical features, diagnosis, and pathogenesis of COVID-CSS with other hematological CSS, namely secondary hemophagocytic lymphohistiocytosis (sHLH), idiopathic multicentric Castleman disease (iMCD), and CAR-T cell therapy associated Cytokine Release Syndrome (CRS). Novel therapeutics targeting cytokines or inhibiting cell signaling pathways have now become the mainstay of treatment in these CSS. We review the evidence for cytokine blockade and attenuation in these known CSS as well as the emerging literature and clinical trials pertaining to COVID-CSS. Established markers of inflammation as well as cytokine levels are compared and contrasted between these four entities in order to establish a foundation for future diagnostic criteria of COVID-CSS.","Blood Rev","England, James T","Abdulla, Alym","Biggs, Catherine M","Lee, Agnes Y Y","Hay, Kevin A","Hoiland, Ryan L","Wellington, Cheryl L","Sekhon, Mypinder","Jamal, Shahin","Shojania, Kamran","Chen, Luke Y C","32425294"],"abstract":["A subset of patients with severe COVID-19 develop profound inflammation and multi-organ dysfunction consistent with a \"Cytokine Storm Syndrome\" (CSS). In this review we compare the clinical features, diagnosis, and pathogenesis of COVID-CSS with other hematological CSS, namely secondary hemophagocytic lymphohistiocytosis (sHLH), idiopathic multicentric Castleman disease (iMCD), and CAR-T cell therapy associated Cytokine Release Syndrome (CRS). Novel therapeutics targeting cytokines or inhibiting cell signaling pathways have now become the mainstay of treatment in these CSS. We review the evidence for cytokine blockade and attenuation in these known CSS as well as the emerging literature and clinical trials pertaining to COVID-CSS. Established markers of inflammation as well as cytokine levels are compared and contrasted between these four entities in order to establish a foundation for future diagnostic criteria of COVID-CSS."],"journal":"Blood Rev","authors":["England, James T","Abdulla, Alym","Biggs, Catherine M","Lee, Agnes Y Y","Hay, Kevin A","Hoiland, Ryan L","Wellington, Cheryl L","Sekhon, Mypinder","Jamal, Shahin","Shojania, Kamran","Chen, Luke Y C"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425294","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.blre.2020.100707","keywords":["covid-19","cytokine release syndrome","cytokine storm syndrome","hemophagocytic lymphohistiocytosis","idiopathic multicentric castleman disease","severe acute respiratory syndrome coronavirus -2 (sars-cov-2)"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667252837925519360,"score":163.60423},{"pmid":32335514,"title":"The Question of Whether to Remain on Therapy for Chronic Rheumatic Diseases in the Setting of the Covid-19 Pandemic.","text":["The Question of Whether to Remain on Therapy for Chronic Rheumatic Diseases in the Setting of the Covid-19 Pandemic.","We appreciate our Italian colleagues' interest in our editorial denoting the rheumatologist's role in helping to diagnose and treat cytokine storm syndrome (CSS) in the setting of the Covid-19 panemic (1). It is encouraging that none of the 123 pediatric rheumatology patients (primarily juvenile idiopathic arthritis) on background biological disease modifying anti-rheumatic drug (bDMARD) therapies in Milan, Italy surveyed over a 7-week period from February 25 through April 14, 2020 (during which time Covid-19 was hyper-endemic there) had either confirmed or suspected Covid-19 (2).","J Rheumatol","Cron, Randy Q","Chatham, W Winn","32335514"],"abstract":["We appreciate our Italian colleagues' interest in our editorial denoting the rheumatologist's role in helping to diagnose and treat cytokine storm syndrome (CSS) in the setting of the Covid-19 panemic (1). It is encouraging that none of the 123 pediatric rheumatology patients (primarily juvenile idiopathic arthritis) on background biological disease modifying anti-rheumatic drug (bDMARD) therapies in Milan, Italy surveyed over a 7-week period from February 25 through April 14, 2020 (during which time Covid-19 was hyper-endemic there) had either confirmed or suspected Covid-19 (2)."],"journal":"J Rheumatol","authors":["Cron, Randy Q","Chatham, W Winn"],"date":"2020-04-27T11:00:00Z","year":2020,"_id":"32335514","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.3899/jrheum.200492","locations":["Italian","Milan","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1666138494100045825,"score":149.19116},{"pmid":32438839,"title":"Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients?","text":["Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients?","The coronavirus disease-19 (COVID-19) has spread over many countries and regions since the end of 2019, becoming the most severe public health event at present. Most of the critical cases developed multiple organ dysfunction, including acute kidney injury (AKI). Cytokine storm syndrome (CSS) may complicate the process of severe COVID-19 patients. This manuscript reviews the different aspects of blood purification in critically ill patients with AKI and increased inflammatory factors, and examines its potential role in severe COVID-19 treatment. Continuous renal replacement therapy (CRRT) has been practiced in many sepsis patients with AKI. Still, the timing and dosing need further robust evidence. In addition to the traditional CRRT, the high-throughput membrane with adsorption function and cytokine adsorption column are two representatives of recently emerging novel membrane technologies. Their potential in removing inflammatory factors and other toxins prospects for the treatment of severe COVID-19.","Ren Fail","Chen, Gang","Zhou, Yangzhong","Ma, Jie","Xia, Peng","Qin, Yan","Li, Xuemei","32438839"],"abstract":["The coronavirus disease-19 (COVID-19) has spread over many countries and regions since the end of 2019, becoming the most severe public health event at present. Most of the critical cases developed multiple organ dysfunction, including acute kidney injury (AKI). Cytokine storm syndrome (CSS) may complicate the process of severe COVID-19 patients. This manuscript reviews the different aspects of blood purification in critically ill patients with AKI and increased inflammatory factors, and examines its potential role in severe COVID-19 treatment. Continuous renal replacement therapy (CRRT) has been practiced in many sepsis patients with AKI. Still, the timing and dosing need further robust evidence. In addition to the traditional CRRT, the high-throughput membrane with adsorption function and cytokine adsorption column are two representatives of recently emerging novel membrane technologies. Their potential in removing inflammatory factors and other toxins prospects for the treatment of severe COVID-19."],"journal":"Ren Fail","authors":["Chen, Gang","Zhou, Yangzhong","Ma, Jie","Xia, Peng","Qin, Yan","Li, Xuemei"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32438839","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1080/0886022X.2020.1764369","keywords":["covid-19","cytosorb","acute kidney injury","blood purification","cytokine storm","oxiris"],"topics":["Treatment"],"weight":1,"_version_":1667535119564406784,"score":125.37296},{"pmid":32277367,"pmcid":"PMC7145936","title":"Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.","text":["Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.","The ongoing pandemic coronavirus disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of global concern. Environmental factors such as air pollution and smoking and comorbid conditions (hypertension, diabetes mellitus and underlying cardio-respiratory illness) likely increase the severity of COVID-19. Rheumatic manifestations such as arthralgias and arthritis may be prevalent in about a seventh of individuals. COVID-19 can result in acute interstitial pneumonia, myocarditis, leucopenia (with lymphopenia) and thrombocytopenia, also seen in rheumatic diseases like lupus and Sjogren's syndrome. Severe disease in a subset of patients may be driven by cytokine storm, possibly due to secondary hemophagocytic lymphohistiocytosis (HLH), akin to that in systemic onset juvenile idiopathic arthritis or adult-onset Still's disease. In the absence of high-quality evidence in this emerging disease, understanding of pathogenesis may help postulate potential therapies. Angiotensin converting enzyme 2 (ACE2) appears important for viral entry into pneumocytes; dysbalance in ACE2 as caused by ACE inhibitors or ibuprofen may predispose to severe disease. Preliminary evidence suggests potential benefit with chloroquine or hydroxychloroquine. Antiviral drugs like lopinavir/ritonavir, favipiravir and remdesivir are also being explored. Cytokine storm and secondary HLH might require heightened immunosuppressive regimens. Current international society recommendations suggest that patients with rheumatic diseases on immunosuppressive therapy should not stop glucocorticoids during COVID-19 infection, although minimum possible doses may be used. Disease-modifying drugs should be continued; cessation may be considered during infection episodes as per standard practices. Development of a vaccine may be the only effective long-term protection against this disease.Key Points* Patients with coronavirus disease 19 (COVID-19) may have features mimicking rheumatic diseases, such as arthralgias, acute interstitial pneumonia, myocarditis, leucopenia, lymphopenia, thrombocytopenia and cytokine storm with features akin to secondary hemophagocytic lymphohistiocytosis.* Although preliminary results may be encouraging, high-quality clinical trials are needed to better understand the role of drugs commonly used in rheumatology like hydroxychloroquine and tocilizumab in COVID-19.* Until further evidence emerges, it may be cautiously recommended to continue glucocorticoids and other disease-modifying antirheumatic drugs (DMARDs) in patients receiving these therapies, with discontinuation of DMARDs during infections as per standard practice.","Clin Rheumatol","Misra, Durga Prasanna","Agarwal, Vikas","Gasparyan, Armen Yuri","Zimba, Olena","32277367"],"abstract":["The ongoing pandemic coronavirus disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of global concern. Environmental factors such as air pollution and smoking and comorbid conditions (hypertension, diabetes mellitus and underlying cardio-respiratory illness) likely increase the severity of COVID-19. Rheumatic manifestations such as arthralgias and arthritis may be prevalent in about a seventh of individuals. COVID-19 can result in acute interstitial pneumonia, myocarditis, leucopenia (with lymphopenia) and thrombocytopenia, also seen in rheumatic diseases like lupus and Sjogren's syndrome. Severe disease in a subset of patients may be driven by cytokine storm, possibly due to secondary hemophagocytic lymphohistiocytosis (HLH), akin to that in systemic onset juvenile idiopathic arthritis or adult-onset Still's disease. In the absence of high-quality evidence in this emerging disease, understanding of pathogenesis may help postulate potential therapies. Angiotensin converting enzyme 2 (ACE2) appears important for viral entry into pneumocytes; dysbalance in ACE2 as caused by ACE inhibitors or ibuprofen may predispose to severe disease. Preliminary evidence suggests potential benefit with chloroquine or hydroxychloroquine. Antiviral drugs like lopinavir/ritonavir, favipiravir and remdesivir are also being explored. Cytokine storm and secondary HLH might require heightened immunosuppressive regimens. Current international society recommendations suggest that patients with rheumatic diseases on immunosuppressive therapy should not stop glucocorticoids during COVID-19 infection, although minimum possible doses may be used. Disease-modifying drugs should be continued; cessation may be considered during infection episodes as per standard practices. Development of a vaccine may be the only effective long-term protection against this disease.Key Points* Patients with coronavirus disease 19 (COVID-19) may have features mimicking rheumatic diseases, such as arthralgias, acute interstitial pneumonia, myocarditis, leucopenia, lymphopenia, thrombocytopenia and cytokine storm with features akin to secondary hemophagocytic lymphohistiocytosis.* Although preliminary results may be encouraging, high-quality clinical trials are needed to better understand the role of drugs commonly used in rheumatology like hydroxychloroquine and tocilizumab in COVID-19.* Until further evidence emerges, it may be cautiously recommended to continue glucocorticoids and other disease-modifying antirheumatic drugs (DMARDs) in patients receiving these therapies, with discontinuation of DMARDs during infections as per standard practice."],"journal":"Clin Rheumatol","authors":["Misra, Durga Prasanna","Agarwal, Vikas","Gasparyan, Armen Yuri","Zimba, Olena"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32277367","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s10067-020-05073-9","keywords":["covid-19","epidemiology","hydroxychloroquine","hypothesis","immunity","pathogenesis","vaccines","vitamin d"],"locations":["thrombocytopenia","Cytokine","myocarditis","leucopenia","lymphopenia","thrombocytopenia"],"e_drugs":["Hydroxychloroquine","remdesivir","lopinavir-ritonavir drug combination","Ibuprofen","Chloroquine","tocilizumab","favipiravir"],"topics":["Treatment"],"weight":1,"_version_":1666138491608629250,"score":119.219284}]}